Lin Shen

4.0k total citations
33 papers, 829 citations indexed

About

Lin Shen is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Lin Shen has authored 33 papers receiving a total of 829 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 7 papers in Pathology and Forensic Medicine. Recurrent topics in Lin Shen's work include Colorectal Cancer Treatments and Studies (14 papers), Gastric Cancer Management and Outcomes (13 papers) and Genetic factors in colorectal cancer (6 papers). Lin Shen is often cited by papers focused on Colorectal Cancer Treatments and Studies (14 papers), Gastric Cancer Management and Outcomes (13 papers) and Genetic factors in colorectal cancer (6 papers). Lin Shen collaborates with scholars based in China, United States and South Korea. Lin Shen's co-authors include Rui‐Hua Xu, Jianming Xu, Hongming Pan, Jing Gao, Tianshu Liu, Yuxian Bai, Zhihao Lü, Yilin Li, Shukui Qin and Yanyan Li and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Scientific Reports.

In The Last Decade

Lin Shen

30 papers receiving 817 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lin Shen China	11	577	443	174	164	163	33	829
Akiko Kawano Nagatsuma Japan	12	381 0.7×	387 0.9×	101 0.6×	153 0.9×	92 0.6×	16	653
Madeleine Hewish United Kingdom	8	393 0.7×	340 0.8×	293 1.7×	217 1.3×	205 1.3×	20	854
Valerie Poulart United States	13	684 1.2×	283 0.6×	127 0.7×	114 0.7×	249 1.5×	17	1.0k
Yuezong Bai China	15	629 1.1×	402 0.9×	158 0.9×	149 0.9×	268 1.6×	60	987
P. Fidias United States	14	882 1.5×	971 2.2×	87 0.5×	165 1.0×	116 0.7×	39	1.3k
M Starnawski Austria	3	466 0.8×	660 1.5×	124 0.7×	271 1.7×	55 0.3×	5	862
Mitsutoshi Tatsumi Japan	9	337 0.6×	394 0.9×	93 0.5×	228 1.4×	46 0.3×	25	756
Swantje Held Germany	17	920 1.6×	444 1.0×	318 1.8×	230 1.4×	210 1.3×	85	1.1k
Claire Saffery United Kingdom	7	569 1.0×	628 1.4×	114 0.7×	331 2.0×	51 0.3×	17	886
Andrzej Szawłowski Poland	8	602 1.0×	266 0.6×	49 0.3×	171 1.0×	226 1.4×	21	836

Countries citing papers authored by Lin Shen

Since Specialization

Citations

This map shows the geographic impact of Lin Shen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lin Shen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lin Shen more than expected).

Fields of papers citing papers by Lin Shen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lin Shen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lin Shen. The network helps show where Lin Shen may publish in the future.

Co-authorship network of co-authors of Lin Shen

This figure shows the co-authorship network connecting the top 25 collaborators of Lin Shen. A scholar is included among the top collaborators of Lin Shen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lin Shen. Lin Shen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shen, Lin, Yan Zhang, Zhen Li, et al.. (2025). 2098MO Cadonilimab (Cado) plus chemotherapy (chemo) versus chemotherapy as first-line (1L) treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: Final results of the phase III COMPASSION-15 trial. Annals of Oncology. 36. S1103–S1103.

Zhu, Hong, et al.. (2025). Updated efficacy results of ASKB589 combined with CAPOX and PD-1 inhibitor as first-line treatment for metastatic gastric/gastro-esophageal junction (G/GEJ) adenocarcinoma from a phase Ib/II study.. Journal of Clinical Oncology. 43(4_suppl). 454–454. 3 indexed citations

Xie, Tong, Bohan Zhang, Yang Feng, et al.. (2025). Comparison of immune checkpoint inhibitors in combination with chemotherapy versus chemotherapy alone in the first-line treatment of advanced gastric cancer patients with low PD-L1 expression: a systematic review and meta-analysis. Therapeutic Advances in Medical Oncology. 17. 22781363–22781363. 1 indexed citations

Park, Joon Oh, Yin‐Hsun Feng, Wu‐Chou Su, et al.. (2024). Erdafitinib in Asian patients with advanced solid tumors: an open-label, single-arm, phase IIa trial. BMC Cancer. 24(1). 1006–1006. 9 indexed citations

Shen, Lin, Pengwan Chen, Ying Wan, et al.. (2024). 129MO Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive (HER2+) advanced gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric06 (DG-06) final analysis. Annals of Oncology. 35. S1454–S1455. 2 indexed citations

Wu, Chunhua, Wenfei Li, Qi Zhang, et al.. (2023). Advances in KRAS mutation inhibition in metastatic colorectal cancer. 2(1). 4 indexed citations

Shen, Lin, et al.. (2019). Comparison of CHOP vs CHOPE for treatment of peripheral T-cell lymphoma: a meta-analysis. SHILAP Revista de lepidopterología. 2 indexed citations

Liu, Tianshu, Yanru Qin, Jin Li, et al.. (2019). Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2‐positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial. Cancer Communications. 39(1). 38–38. 23 indexed citations

Xu, Rui‐Hua, Jin Li, Yuxian Bai, et al.. (2017). Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. Journal of Hematology & Oncology. 10(1). 63 indexed citations

10.

Wang, Xicheng, Qing Wei, Jing Gao, et al.. (2017). Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study. Chinese Journal of Cancer. 36(1). 81–81. 14 indexed citations

11.

Gao, Jing, Hai Wang, Beifang Li, et al.. (2017). Circulating tumor DNA functions as an alternative for tissue to overcome tumor heterogeneity in advanced gastric cancer. Cancer Science. 108(9). 1881–1887. 50 indexed citations

12.

Tabernero, Josep, Paulo M. Hoff, Lin Shen, et al.. (2017). Pertuzumab (P) + trastuzumab (H) + chemotherapy (CT) for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (mGC/GEJC): Final analysis of a Phase III study (JACOB). Annals of Oncology. 28. v209–v209. 45 indexed citations

13.

Wang, Yakun, Xicheng Wang, & Lin Shen. (2016). Clinical characteristics, diagnosis, and treatment of brain metastases from colorectal cancer. 43(21). 962–966. 2 indexed citations

14.

Li, Yilin, Jifang Gong, Qiyue Zhang, et al.. (2016). Dynamic monitoring of circulating tumour cells to evaluate therapeutic efficacy in advanced gastric cancer. British Journal of Cancer. 114(2). 138–145. 83 indexed citations

15.

Zhu, Yan, Tiantian Tian, Zhongwu Li, et al.. (2015). Establishment and characterization of patient-derived tumor xenograft using gastroscopic biopsies in gastric cancer. Scientific Reports. 5(1). 8542–8542. 58 indexed citations

16.

Tejpar, Sabine, Lin Shen, Xicheng Wang, & Richard L. Schilsky. (2015). Integrating biomarkers in colorectal cancer trials in the West and China. Nature Reviews Clinical Oncology. 12(9). 553–560. 10 indexed citations

17.

Li, Wenhua, Jianming Xu, Lin Shen, et al.. (2014). Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients. BMC Cancer. 14(1). 986–986. 6 indexed citations

18.

Shen, Lin, Jin Li, Jianming Xu, et al.. (2014). Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). Gastric Cancer. 18(1). 168–176. 184 indexed citations

19.

Hoff, Paulo M., Josep Tabernero, Lin Shen, et al.. (2013). Pertuzumab, Trastuzumab and Chemotherapy in Her2-Positive Metastatic Gastric or Gastro-Oesophageal Junction Cancer: an International Phase III Study (Jacob). Annals of Oncology. 24. iv67–iv67. 9 indexed citations

20.

Li, Yuhong, Fang Wang, Lin Shen, et al.. (2010). EGFR Fluorescence In situ Hybridization Pattern of Chromosome 7 Disomy Predicts Resistance to Cetuximab in KRAS Wild-type Metastatic Colorectal Cancer Patients. Clinical Cancer Research. 17(2). 382–390. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact